SEARCH

SEARCH BY CITATION

Keywords:

  • activation assay;
  • adhesion;
  • degranulation;
  • eosinophil;
  • eosinophil activation

Abstract

  1. Top of page
  2. Abstract
  3. References

A simple microtiter assay for eosinophil activation is described. The assay used 1000–4000 eosinophils/microtiter well, and the design allows for a separate or simultaneous quantitative assessment of eosinophil adhension to protein-coated microtiter wells and degranulation after stimulation with eosinophil-activating factors. The number of adherent eosinophils is quantified indirectly by expressing the amount of eosinophil cationic protein (ECP) extracted from the adherent fraction of cells in percentage of the total amount of ECP extracted from the adherent fraction of cells in percentage of the total amount of ECP extracted from the cells added to the wells. Degranulation is quantified in the same way by expressing the amount of ECP or eosinophil protein X (EPX) released to the supernatant in percentage of the total amount of ECP or EPX. Known eosinophil-activating agents such as PMA, interleukin (IL)-3, IL-5, GM-CSF, and platelet-activating factor (PAF) all induced a time- and does-dependent adhension to albumin-coated wells, whereas L_PAF did not. KInetic experiments showed that most adhesion occurred within the first 15–30 min, reaching a plateau around 60 min. After prolonged incubation, a decline in adhesion was detected. GM-CSF-induced adhesion was completely inhibited by incubation with monoclonal antibodies directed against the common β2-chain (CD18) of the LFA-1, Mac-1, p150,95 complexes. Monoclonal antibodies against CD11a, CD11b, CD11c, VLA-4 ALFA, ICAM-1, VCAM-1, Sialyl-Lem, ELAM-1, and LECAM had no inhibitory effect. Simultaneous monitoring of adhesion and degranulation after stimulation of eosinophils in albumincoated wells with either PMA or GM-CSF showed that adhesion always preceded degranulation. Replacing the albumin coating of the microtiter wells with IgG or secretory IgA augmented both the spontaneous and the PMA- or GM-CSF-stimulated responses. In conclusion, the assay allows dynamic evaluation of eosinophil activationa dn can be used to assess soluble eosinophil-activating factors as well as to study eosinophil activation by solidphase-bound proteins.

Abbreviations.
ECP

eosinophil cationic protein

EPX

eosinophil protein X

ICAM

intracellular adhesion molecule

LFA-1

leukocyte function antigen 1

VLA-4

very late activation antigen

VCAM

vascular cell adhesion molecule

EDTA

ethylenediaminetetraacetic acid

IL-3

interleukin-3

IL-5

interleukin-5

GM-CSF

granulocyte/ macrophage colony stimulating factor

PAF

platelet-activating factor

PMA

phorbol 12-myristate 13-acetate

DMEM

Dulbecco's modified Eagle's medium

HSA

human serum albumin

PBS

phosphate-buffered saline

References

  1. Top of page
  2. Abstract
  3. References
  • 1
    Butterworth AE, Sturrock RF, Houba D, Mahmoud AAF, Sher A, Rees PH. Eosinophils as mediators of antibody-dependent damage to schistosomula. Nature 1975;256:7279.
  • 2
    David JR, Butterworth AE, Azevedo de Brito P, et al. Enhanced helminthotoxic capacity of eosinophils from patients with eosinophilia. N Engl J Med 1980;303:114752.
  • 3
    Bochner BS, Luscinskas FW, Gimbrone MA Jr, et al. Adhesion of human basophils, eosinophils and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med 1991;173:15537.
  • 4
    Dobrina A, Menegazzi R, Carlos TM, et al. Mechanisms of eosinophil adherence to cultured vascular endothelial cells. Eosinophils bind to the cytokine-induced ligand vascular cell adhesion molecule-1 via the very late activation antigen-4 integrin receptor. J Clin Invest 1991;88:206.
  • 5
    Kimani G, Tonnese MG, Henson PM. Stimulation of eosinophil adherence to vascular endothelial cells in vitro by platelet activating factor. J Immunol 1988;140:31616.
  • 6
    Walsh GM, Hartnell A, Wardlaw AJ, et al. IL-5 enhances the in vitro adhesion of human eosinophils, but not neutrophils, in a leucocyte integrin (CD11/18)-dependent manner. Immunology 1990;71:25865.
  • 7
    Håkanson L, Carlson M. Stålenheim G, Venge P. Migratory responses of eosinophil and neutrophil granulocytes from patients with asthma. J Allergy Clin Immunol 1990;85:74350.
  • 8
    Wardlaw AJ, Moqbel R, Cromwell O, Kay AB. Platelet activating factor: a potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest 1986;78:17016.
  • 9
    Abu-Ghazaleh RI, Fujisawa T, Mestecky J, Kyle RA, Gleich GJ. IgA-induced eosinophil degranulation. J Immunol 1989;142:23932400.
  • 10
    Baskar P, Pinkus SH. Selective regulation of eosinophil degranulation by interleukin 1 beta. Proc Soc Exp Biol Med 1992;199:24954.
  • 11
    Carlson M, Peterson C, Venge P. The influence of IL-3, IL-5, and GM-CSF on normal eosinophil and neutrophil C3b-induced degranulation. Allergy 1993;48:43742.
  • 12
    Fujisawa T, Abu-Ghazelah R, Kita H, Sanderson SJ, Gleich GJ. Regulatory effect of cytokines on eosinophil degranulation. J Immunol 1990;144:6426.
  • 13
    Winqvist I, Olofson T, Olsson I. Mechanisms for eosinophil degranulation; release of the eosinophil cationic protein. Immunology 1984;51:18.
  • 14
    Sedgwick JB, Vrtis RF, Gourley MF, Busse WW. Stimulus-dependent differences in superoxide anion generation by normal human eosinophils and neutrophils. J Allergy Clin Immunol 1988;81:87683.
  • 15
    Shult PA. Graziano FM, Wallow IH, Busse WW. Comparison of superoxide generation and luminol-dependent chemiluminescence with eosinophils and neutrophils from normal individuals. J Lab Clin Med 1985;106:63845.
  • 16
    Lee T Lenihan DJ, Malone B, Roddy LL, Wasserman SI. Increased biosynthesis of platelet activating factor in activated human eosinophils. J Biol Chem 1984;259:552630.
  • 17
    Owen WF Jr, Soberman RJ, Yoshimoto T, Sheffer AL, Lewis RA, Austen KF. Synthesis and release of leukotriene C4 by human eosinophils. J Immunol 1987;138:5328.
  • 18
    Silberstein DS, Owen WF, Gasson JC, et al. Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol 1986;137:32904.
  • 19
    Carlson M, Håkanson L, Peterson C, Stålenheim G, Venge P. Secretion of granule proteins from eosinophils and neutrophils is increased in asthma. J Allergy Clin Immunol 1991;87:2733.
  • 20
    Hansel TT, De-Vries IJ, Iff T, et al. An improved immuno-magnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods 1991;1–2:10510.
  • 21
    Reimert CM. Venge P, Kharazmi A, Bendtzen K. Detection of eosinophil cationic protein (ECP) by an enzyme-linked immunosorbent assay. J Immunol Methods 1991;138:28590.
  • 22
    Reimert CM, Minuva U, Kharazmi A, Bendtzen K. Eosinophil protein X/eosinophil derived neurotoxin (EPX/EDN): detection by enzyme-linked immunosorbent assay and purification from normal human urine. J Immunol Methods 1991;141:97104.
  • 23
    Horie S, Kita H. CD11b/CD18 (Mac-1) is required for degranulation of human eosinophils induced by human recombinant granulocyte-macrophage colony-stimulating factor and platelet activating factor. J Immunol 1994;152:545767.
  • 24
    Takafuji S, Ohtoshi T, Takizawa H, Tadokoro K, Ito K. Eosinophil degranulation in the presence of bronchial epithelial cells. J Immunol 1996;156:39805.
  • 25
    Hartnell A. Moqbel R, Walsh GM, Bradley B, Kay AB. Fc gamma and CD11/CD18 receptor expression on normal density and low density human eosinophils. Immunology 1990;69:26470.
  • 26
    Bach MK, Brashler JR, Sanders ME, Biemkowski MJ. Pitfalls in the quantitative estimation of the secretion of granule proteins by eosinophils. J Immunol Methods 1991;142:24350.
  • 27
    Kaneko M, Horie S, Kato M, Gleich GJ, Kita H. A crucial role for β2 integrin in the activation of eosinophils stimulated by IgG. J Immunol 1996;155:263141.
  • 28
    Carlson M, Oberg G, Peterson C, Venge P. Releasability of human hypereosinophilic eosinophils is related to the density of the cells. Br J Haematol 1994;86:417.
  • 29
    Metcalfe DD, Gadek JE, Raphael GD, Frank MM, Kaplan AP, Kaliner M. Human eosinophil adherence to serum-treated Sepharose: granule-associated enzyme release and requirements of the alternative complement pathway. J Immunol 1977;119:174450.
  • 30
    Peterson CG, Garcia RC, Carlson MGC, Venge P. Eosinophil cationic protein (ECP), eosinophil protein-X (EPX) and eosinophil peroxidase (EPO): granule distribution, degranulation and characterization of released proteins. In: PetersonCGB, editor. Eosinophil granule proteins. Bio-chemical and functional studies. Doctoral thesis, Uppsala University, Sweden, 1987:III, 119.
  • 31
    Anderson DC, Miller LJ, Schmalstieg FC, Rothlein R, Springer TA. Contributions of the Mac-1 glycoprotein family to adherence-dependent granulocyte functions: structure-function assessment employing subunit-specific monoclonal antibodies. J Immunol 1986;137:1527.
  • 32
    Carrera AC, Rincon M, Sanchez-Madrid F, Lopez-Botet M, Delandazuri MO. Triggering of co-mitogenic signals in T-cell proliferation by anti-LFA-1 (CD18, CD11a), LFA3, and CD7 monoclonal antibodies. J Immunol 1988;141:101924.
  • 33
    Egesten A, Gullberg U, Olsson I, Richter J. Phorbol ester-induced degranulation in adherent human eosinophil granulocytes is dependent on CD11/CD18 leukocyte integrins. J Leukoc Biol 1993;53:28793.
  • 34
    Natan C, Srimal S, Farber C, et al. Cytokine-induced respiratory burst of human neutrophils: dependence on extracellular matrix proteins and CD11/CD18 integrins. J Cell Biol 1989;109:13419.
  • 35
    Horie S, Gleich GJ, Kita H. Cytokines directly induce degranulation and superoxide production from human eosinophils. J Allergy Clin Immunol 1996;98:37181.
  • 36
    Håkanson L, Søegaard Nielsen L, Teder P. Measurement of neutrophil and eosinophil adhesion to E-selectin, VCAM-1, and ICAM-1 by the use of transfected fibroblast cell lines. J Immunol Methods 1994;176:5366.
  • 37
    Tai P-C, Spry CJF, Peterson C, Venge P, Olsson I. Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein. Nature 1984;309:1823.
  • 38
    Wardlaw A. Eosinophil density: what does it mean Clin Exp Allergy 1995;25:11459.
  • 39
    Kita H, Horie S, Gleich GJ. Extracellular matrix proteins attenuate activation and degranulation of stimulated eosinophils. J Immunol 1996;156:117481.